Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International
In her new role, Ms. Rossi will join the executive management team and have overall responsibility for commercial strategy and operations, including sales and marketing, for a potential commercial launch of avapritinib in
"We are thrilled to welcome Christy to
Mr. Albers continued, "We are also thrilled to have Paul join
Ms. Rossi brings nearly 20 years of global pharmaceutical and biotechnology experience. Most recently, Ms. Rossi served as the Multiple Sclerosis (MS) Business Unit Head,
"I'm excited to join the
Mr. Beresford joins
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding a potential commercial launch of avapritinib in
Trademarks
TYSABRI® is a registered trademark of
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-strengthens-leadership-with-the-appointments-of-christina-rossi-as-chief-commercial-officer-and-paul-beresford-as-general-manager-international-300739612.html
SOURCE
Investor and Media Relations Contacts: Kristin Hodous, 617-714-6674, KHodous@blueprintmedicines.com or Jim Baker, 617-844-8236, JBaker@blueprintmedicines.com